Search hospitals > Wisconsin > Burlington
Aurora Cancer Care-Southern Lakes VLCC
Claim this profileBurlington, Wisconsin 53105
Global Leader in Parotid Gland Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Breast cancer
Conducts research for Non-Small Cell Lung Cancer
184 reported clinical trials
21 medical researchers
Summary
Aurora Cancer Care-Southern Lakes VLCC is a medical facility located in Burlington, Wisconsin. This center is recognized for care of Parotid Gland Cancer, Breast Cancer, Lung Cancer, Breast cancer, Non-Small Cell Lung Cancer and other specialties. Aurora Cancer Care-Southern Lakes VLCC is involved with conducting 184 clinical trials across 293 conditions. There are 21 research doctors associated with this hospital, such as Thomas J. Saphner, Rubina Qamar, Antony Ruggeri, and Michael A Thompson.Area of expertise
1Parotid Gland Cancer
Global LeaderStage IV
Stage III
Stage II
2Breast Cancer
Global LeaderER positive
HER2 negative
HER2 positive
Top PIs
Thomas J. SaphnerAurora Saint Luke's Medical Center1 year of reported clinical research
Expert in Parotid Gland Cancer
Studies Breast Cancer
30 reported clinical trials
68 drugs studied
Rubina QamarAurora Saint Luke's Medical Center4 years of reported clinical research
Studies Parotid Gland Cancer
Studies Lung Cancer
24 reported clinical trials
68 drugs studied
Antony RuggeriAurora Cancer Care-Milwaukee West4 years of reported clinical research
Studies Parotid Gland Cancer
Studies Colon Cancer
14 reported clinical trials
57 drugs studied
Michael A ThompsonAurora Cancer Care-Milwaukee West4 years of reported clinical research
Studies Multiple Myeloma
Studies Plasma Cell Neoplasm
12 reported clinical trials
29 drugs studied
Clinical Trials running at Aurora Cancer Care-Southern Lakes VLCC
Breast Cancer
Lung Cancer
Cancer
Parotid Gland Cancer
Breast cancer
Non-Small Cell Lung Cancer
Multiple Myeloma
Bladder Cancer
Bladder Carcinoma
Prostate Cancer
Durvalumab + Chemotherapy
for Breast Cancer
This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint High 2 Risk (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as paclitaxel, doxorubicin, and cyclophosphamide work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. There is some evidence from previous clinical trials that people who have a MammaPrint High 2 Risk result may be more likely to respond to chemotherapy and immunotherapy. Adding durvalumab to usual chemotherapy may be able to prevent the cancer from returning for patients with MP2 stage II-III hormone receptor positive, HER2 negative breast cancer.
Recruiting2 awards Phase 340 criteria
Hormone Therapy with or without Radiation
for Breast Cancer
This Phase III Trial evaluates whether breast conservation surgery and endocrine therapy results in a non-inferior rate of invasive or non-invasive ipsilateral breast tumor recurrence (IBTR) compared to breast conservation with breast radiation and endocrine therapy.
Recruiting2 awards Phase 313 criteria
Low Dose Tamoxifen
for Breast Cancer
This phase III trial compares the effect of low dose tamoxifen to usual hormonal therapy, including aromatase inhibitors, in treating post-menopausal women with hormone positive, HER2 negative early stage breast cancer. Tamoxifen is in a class of medications known as antiestrogens. It blocks the activity of estrogen (a female hormone) in the breast. This may stop the growth of some breast tumors that need estrogen to grow. Aromatase inhibitors, such as anastrozole, letrozole, and exemestane, prevent the formation of estradiol, a female hormone, by interfering with an aromatase enzyme. Aromatase inhibitors are used as a type of hormone therapy to treat postmenopausal women with hormone-dependent breast cancer. Giving low dose tamoxifen may be more effective compared to usual hormone therapy in treating post-menopausal women with hormone-positive, HER2 negative early stage breast cancer.
Recruiting2 awards Phase 38 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Aurora Cancer Care-Southern Lakes VLCC?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.